Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease

Transplantation

Volumn 92, Issue 6, 2011, Pages

  Choi, Hong Seok ^a   Kim, Sung Yong ^a   Lee, Jong Ho ^a   Yoon, So Young ^a   Cho, Yo Han ^a   Lee, Hong Ghi ^a  

^a Konkuk University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACICLOVIR; ALTEPLASE; COTRIMOXAZOLE; FLUDARABINE; MELPHALAN; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CASE REPORT; DIABETIC NEPHROPATHY; DIARRHEA; ENGRAFTMENT; EPSTEIN BARR VIRUS; ERYTHROPHAGOCYTOSIS; FEVER; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KARYOTYPE 46,XY; KIDNEY FAILURE; LETTER; LIVER DISEASE; MALE; PANCYTOPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SINUSOIDAL OBSTRUCTION SYNDROME; THERAPY RESISTANCE; WHOLE BODY RADIATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RENAL DIALYSIS; RISK; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 80052656200     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822a79f1     Document Type: Letter

References (9)

1. Horwitz ME, Spasojevic I, Morris A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: Clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant 2007; 13: 1422.
2. Gerrie A, Marsh J, Lipton JH, et al. Marrow transplantation for severe aplastic anemia with significant renal impairment. Bone Marrow Transplant 2007; 39: 311.
3. Hamaki T, Katori H, Kami M, et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant 2002; 30: 195.
4. Turkistani W, Ashour M, Al-Mojalli H, et al. Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine. Bone Marrow Transplant. 2010; 45: 415.
5. Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555.
6. Tendas A, Cupelli L, Dentamaro T, et al. Feasibility of a dose-adjusted fludarabinemelphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Ann Hematol 2009; 88: 285.
7. Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 2002; 20: 904.
8. Lim WH, Kireta S, Leedham E, et al. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007; 72: 1138.
9. Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59: 1382.